BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2024 Earnings Call Transcript August 5, 2024BioCryst Pharmaceuticals, Inc. beats earnings expectations.
Biocryst Pharmaceuticals Inc (BCRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 12,570,000 | $77,682,600 | -4% | 1.03% |
| 2. | Kynam Capital Derrick Tang | 8,826,710 | $54,549,068 | +36% | 4.2% |
| 3. | Deerfield Management James E. Flynn | 8,135,804 | $50,279,269 | +63% | 0.83% |
| 4. | Alkeon Capital Management Panayotis Takis Sparaggis | 7,099,484 | $43,874,811 | +74% | 0.07% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 3,619,258 | $22,367,014 | +4% | 0.67% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.36 | 7,861 | Director | 44,951 | 2024-05-30 | Filing | |
| $6.40 | 2,500 | Director | 2,500 | 2024-05-24 | Filing | |
| $6.38 | 5,000 | Director | 86,818 | 2024-05-20 | Filing | |
| $6.25 | 15,000 | Director | 66,997 | 2024-05-20 | Filing | |
| $5.57 | 36,300 | Officer | 266,744 | 2024-05-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.32 | 8,600 | Director | 27,831 | 2024-06-24 | Filing | |
| $6.00 | 4,689 | Director | 27,742 | 2024-06-17 | Filing | |
| $6.11 | 6,698 | Director | 52,852 | 2024-06-14 | Filing | |
| $7.98 | 4,000 | Director | 25,611 | 2023-06-15 | Filing | |
| $8.04 | 12,866 | Director | 81,818 | 2023-06-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,681,370 | $111,901,408 | 0% | |
| 2. | 17,763,720 | $106,404,682 | 0% | |
| 3. | 12,777,003 | $76,534,248 | 0% | |
| 4. | 4,260,638 | $25,524,572 | 0% | |
| 5. | 3,846,154 | $23,038,463 | 15.49% |
News See All
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23.
12 Best Depressed Stocks To Buy in 2024
JPMorgan Chief Jamie Dimon, in his latest letter to shareholders, has warned that the real odds of soft landing a quite low when compared to market expectations.
13 Best Biotech Stocks To Buy Under $20
In this article, we're going to take a look at 13 best biotech stocks to buy under $20.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.24. BioCryst Pharmaceuticals, Inc.
5 Best Medical Stocks to Buy Under $10
In this article, we will take a look at the 5 best medical stocks to buy under $10.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to the BioCryst Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to the BioCryst Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference to Mr.
5 Best Medical Stocks Under $10
In this piece, we will take a look at the five best medical stocks under $10.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2023 Earnings Call Transcript
Operator: Good morning and welcome to the BioCryst Q1 2023 Earnings Conference Call. Please note this event is being recorded. I would now like to turn the conference to John Bluth at BioCryst.